Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors

BackgroundSeveral studies have evaluated the relationship between tumor mutational burden (TMB) and outcomes of immune checkpoint inhibitors. In the phase II KEYNOTE-158 study of pembrolizumab monotherapy for previously treated recurrent or metastatic cancer, high TMB as assessed by the FoundationOn...

Full description

Saved in:

Bibliographic Details
Published in:	Journal for immunotherapy of cancer Vol. 10; no. 1; p. e003091
Main Authors:	Cristescu, Razvan, Aurora-Garg, Deepti, Albright, Andrew, Xu, Lei, Liu, Xiao Qiao, Loboda, Andrey, Lang, Lixin, Jin, Fan, Rubin, Eric H, Snyder, Alexandra, Lunceford, Jared
Format:	Journal Article
Language:	English
Published:	England BMJ Publishing Group Ltd 01.01.2022 BMJ Publishing Group LTD BMJ Publishing Group
Series:	Original research
Subjects:	Aged Antibodies, Monoclonal, Humanized - therapeutic use B7-H1 Antigen - metabolism Biomarkers, Tumor - genetics Cancer Cell death Chemotherapy FDA approval Female Gene expression Genomes Humans Immune checkpoint inhibitors Immune Checkpoint Inhibitors - therapeutic use Immunotherapy Immunotherapy Biomarkers Laboratories Lung cancer Male Melanoma Metastasis Microsatellite Instability Monoclonal antibodies Mutation Neoplasms - drug therapy Neoplasms - genetics Neoplasms - metabolism programmed cell death 1 receptor Regulatory approval Retrospective Studies Targeted cancer therapy Treatment Outcome tumor biomarkers Tumors Whole Exome Sequencing United States > US Massachusetts California programmed cell death 1 receptor tumor biomarkers immunotherapy
ISSN:	2051-1426, 2051-1426
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!